Absci (ABSI) Net Cash Flow Growth (1y) (2021 - 2026)
Absci (ABSI) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 53.46% |
| 10 | Absci | 1.17 Bn | 1.04 Bn | - | -292.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -292.67% |
| Dec 31, 2025 | -289.00% |
| Sep 30, 2025 | -422.74% |
| Jun 30, 2025 | 43.79% |
| Mar 31, 2025 | 144.24% |
| Dec 31, 2024 | 9.43% |
| Sep 30, 2024 | -161.42% |
| Jun 30, 2024 | -131.64% |
| Mar 31, 2024 | 72.47% |
| Dec 31, 2023 | 105.92% |
| Sep 30, 2023 | 108.97% |
| Jun 30, 2023 | 277.63% |
| Mar 31, 2023 | -66.96% |
| Dec 31, 2022 | -77.42% |
| Sep 30, 2022 | -154.88% |
| Jun 30, 2022 | 52.03% |
| Mar 31, 2022 | -125.63% |
| Dec 31, 2021 | -143.78% |
| Sep 30, 2021 | 4,890.09% |